Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients

Transplant International

Volumn 10, Issue 6, 1997, Pages 462-465

  Gavaldà, Joan ^a   De Otero, Jordi ^a   Murio, Enric ^b   Vargas, Victor ^b   Rosselló, José ^b   Calicó, Ignasi ^b   Margarit, Carles ^b   Pahissa, Albert ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acyclovir, cytomegalovirus, liver transplantation; Cytomegalovirus, liver transplantation, acyclovir; Liver transplantation, cytomegalovirus, acyclovir

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; ANTIVIRAL AGENTS; BLOOD; CREATININE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HALLUCINATIONS; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RABBITS; SPAIN; SURVIVAL RATE; TIME FACTORS;

EID: 0030777001     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001470050087     Document Type: Article

References (10)

1. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd D (1989) A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320: 1381-1387
2. Barkholt LM, Ericzon BG, Ehrnst A, Forsgren M, Andersson JP (1990) Cytomegalovirus infections in liver transplant patients: incidence and outcome. Transplant Proc 22: 238-240
3. Elkins CC, Frist WH, Dummer S, Stewart JR, Merrill WH, Carden KA, Bender HW Jr (1993) Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated? Ann Thorac Surg 56: 1267-1273
4. Martin M, Man̄ez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ondick L, Ptachinski R, Irish W, Kisor D (1994) A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 58: 779-785
5. Mollison LC, Richards MJ, Johnson PDR, Haves K, Munckhof WJ, Jones RM, Dabkowski PD, Angus PW (1993) High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis 168: 721-724
6. Paya CV, Marin E, Keating M, Dickson R, Porayko M, Wiesner R (1993) Solid organ transplantation: results and implications of acyclovir use in liver transplants. J Med Virol 1: 123-127
7. Rubin RH (1994) Infection in the organ transplant recipient. In: Rubin RH, Young LS (eds), Clinical approach to infection in the compromised host. Medical Book Company, New York, pp 629-705
8. Saliba F, Eyraud D, Samuel MF, David MF, Arulnaden JL, Dussaix E, Mathieu D, Bismuth H (1993) Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 25: 1444-1445
9. Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Wood RP, Langnas AN, Reed EC, Woods GL, Donovan GP, Pillen TJ, Li R, Duckworth RM, Shaw BW(1991) Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 51: 90-97
10. Winston JD, Wirin D, Shaked A, Busuttil RW (1995) Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346: 69-74